Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
NATCO PHARMA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NATCO PHARMA Mar-23 |
TEVA PHARMA Dec-13 |
NATCO PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 847 | 3,486 | - | |
Low | Rs | 502 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 148.4 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 39.2 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 48.2 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 5.50 | 109.40 | - | |
Avg Dividend yield | % | 0.8 | 3.4 | 24.3% | |
Book value per share (Unadj.) | Rs | 267.1 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 182.47 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 4.5 | 1.6 | 279.2% | |
Avg P/E ratio | x | 17.2 | 26.1 | 66.0% | |
P/CF ratio (eoy) | x | 14.0 | 11.4 | 123.2% | |
Price / Book Value ratio | x | 2.5 | 1.5 | 172.3% | |
Dividend payout | % | 14.0 | 87.5 | 16.0% | |
Avg Mkt Cap | Rs m | 123,049 | 2,761,843 | 4.5% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 4,867 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,071 | 1,696,422 | 1.6% | |
Other income | Rs m | 1,285 | 0 | - | |
Total revenues | Rs m | 28,356 | 1,696,422 | 1.7% | |
Gross profit | Rs m | 9,117 | 464,566 | 2.0% | |
Depreciation | Rs m | 1,638 | 137,123 | 1.2% | |
Interest | Rs m | 145 | 33,320 | 0.4% | |
Profit before tax | Rs m | 8,619 | 294,122 | 2.9% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 1,466 | -3,591 | -40.8% | |
Profit after tax | Rs m | 7,153 | 105,974 | 6.7% | |
Gross profit margin | % | 33.7 | 27.4 | 123.0% | |
Effective tax rate | % | 17.0 | -1.2 | -1,393.2% | |
Net profit margin | % | 26.4 | 6.2 | 423.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 30,003 | 1,145,757 | 2.6% | |
Current liabilities | Rs m | 6,831 | 999,197 | 0.7% | |
Net working cap to sales | % | 85.6 | 8.6 | 990.8% | |
Current ratio | x | 4.4 | 1.1 | 383.0% | |
Inventory Days | Days | 63 | 91 | 69.9% | |
Debtors Days | Days | 115 | 96 | 120.3% | |
Net fixed assets | Rs m | 26,571 | 554,089 | 4.8% | |
Share capital | Rs m | 365 | 4,176 | 8.7% | |
Net worth | Rs m | 48,738 | 1,884,403 | 2.6% | |
Long term debt | Rs m | 0 | 867,418 | 0.0% | |
Total assets | Rs m | 56,574 | 3,876,868 | 1.5% | |
Interest coverage | x | 60.4 | 9.8 | 615.0% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.4 | 109.4% | |
Return on assets | % | 12.9 | 3.6 | 359.0% | |
Return on equity | % | 14.7 | 5.6 | 261.0% | |
Return on capital | % | 18.0 | 4.9 | 364.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,491 | 270,322 | 3.1% | |
From Investments | Rs m | -4,771 | -95,786 | 5.0% | |
From Financial Activity | Rs m | -3,630 | -324,269 | 1.1% | |
Net Cashflow | Rs m | 208 | -149,733 | -0.1% |
Compare NATCO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare NATCO PHARMA With: CONCORD DRUGS ALEMBIC THEMIS MEDICARE BIOFIL CHEMICALS GUJ.INJ(KER)
It was indeed a volatile trading session for Indian share markets yesterday.